CBS News just published a story highlighting the promise of Adaptive’s QuanTILfy test that is being tested in many solid tumors for the prognosis, diagnosis, and monitoring of cancer patients. The article is based on a study published yesterday in Science Translational Medicine demonstrating that QuanTILfy may help predict survival in ovarian cancer patients.
Latest Press Releases
Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
Adaptive and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.
Adaptive Biotechnologies Publishes ‘Gold Standard’ Method for Sequencing Cells of the Adaptive Immune System
Adaptive announced today the publication of a method to significantly improve the accuracy of next-generation immune system profiling by creating a fully validated Synthetic Immune System (SISTM) to control for any possible bias caused by the amplification method used to characterize the enormous complexity of the adaptive immune system. The SIS method, developed and validated in Adaptive’s Seattle laboratories is described in the October 25th issue of Nature Communications, and demonstrates the Company’s fundamental commitment to data quality.
Adaptive announced today that Robert Rosen, a seasoned executive and director, is joining the Board of Directors. Mr. Rosen serves as director to the private debt group, Ares Capital Corporation and Ares Commercial Real Estate (NASDAQ: ACRE), and as operating partner of Ares Management, a $65 billion diversified asset management company.
Adaptive Biotechnologies Receives Critical Intellectual Property for Next Generation Immunosequencing Field
Adaptive announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled “Method of Measuring Adaptive Immunity,” exclusively licensed by Adaptive Biotechnologies from the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies CEO Highlighting Companies Oncology Diagnostics Portfolio at Precision Medicine Conference in New York City
Adaptive CEO, Chad Robins, will be highlighting the companies’ pipeline of oncology diagnostics in a 30 minute presentation on October 10th at the Precision Medicine conference in NYC. Mr. Robins will focus on Adaptive’s state-of-the-art immune sequencing assays that are being used to discover and develop applications for prognosis, diagnosis, and monitoring over the life cycle of a cancer patient
Adaptive announced results from an ovarian cancer study, conducted in collaboration with Fred Hutchinson Cancer Research Center, highlighting the even distribution of immune fighter cells (T-cells) within the tumor. The study, published online in The Journal of Pathology ahead of the print publication, demonstrated the ability of Adaptive’s immunoSEQTM assay to assess the quantity and clonality of immune system cells within a tumor at a depth and specificity made possible by next-generation sequencing.
Adaptive Biotechnologies CEO in “Fireside Chat” at Harvard Medical School Cancer Advance Conference; Discussing Company’s Pipeline of Immunotherapy Diagnostics
Adaptive CEO, Chad Robins, will join Nils Longberg, Senior Vice President Biologics Discovery, from Bristol Myers Squibb in a “fireside chat” panel at the Cancer Advance Conference at Harvard Medical School on September 19th, 2013.
Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
Adaptive announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient’s adaptive immune system to fight infection after a cord blood transplant.
Adaptive Biotechnologies received complimentary coverage today on National Public Radio’s “Latest News in Biotech” segment with Luke Zimmerman.